丨 2025年8月19日星期二丨 NO.1久吾高科：拟发行可转债募资不超5.04亿元 8月18日，久吾高科（300631）公告称，公司拟发行可转债募资不超过5.04亿元，扣除发行费用后用 于"班戈错盐湖年产2000吨氯化锂中试生产线BOT项目""特种无机膜组件及装置生产线项目""补充流动 资金"。 8月18日，蔚蓝锂芯公告称，公司控股子公司淮安澳洋顺昌光电技术有限公司拟在马来西亚进行LED项 目建设投资，项目总投资8388万美元，新建LED CSP项目(CSP意为芯片级封装)。项目全部建成达产 后，预计将形成700KK(1KK即1百万)芯片点测分选及CSP月产能。蔚蓝锂芯同日披露2025年半年报，公 司上半年实现归母净利润3.33亿元，同比增长99.09%。 点评：蔚蓝锂芯控股子公司在马来西亚投资建设LED CSP项目，表明蔚蓝锂芯积极拓展国际市场，希望 增强全球竞争力，这会对LED行业产生积极影响。 NO.3龙佰集团：公司上半年净利润13.85亿元同比下降19.53% 8月18日，龙佰集团（002601）公告称，公司2025年上半年实现营业收入133.31亿元，同比下降3.34%， 归母净利润为13.85亿 ...

8月18日，久吾高科公告称，公司拟发行可转债募资不超过5.04亿元，扣除发行费用后用于"班戈错盐湖 年产2000吨氯化锂中试生产线BOT项目""特种无机膜组件及装置生产线项目""补充流动资金"。 点评：久吾高科拟发行可转债募资，募投项目展现其在新能源和环保领域的战略布局。此举有望增强公 司竞争力，提升市场份额，对相关行业产生积极影响。 NO.2 蔚蓝锂芯：控股子公司拟以8388万美元在马来西亚投建LED项目 8月18日，蔚蓝锂芯公告称，公司控股子公司淮安澳洋顺昌光电技术有限公司拟在马来西亚进行LED项 目建设投资，项目总投资8388万美元，新建LED CSP项目（CSP意为芯片级封装）。项目全部建成达产 后，预计将形成700KK（1KK即1百万）芯片点测分选及CSP月产能。蔚蓝锂芯同日披露2025年半年 报，公司上半年实现归母净利润3.33亿元，同比增长99.09%。 点评：蔚蓝锂芯控股子公司在马来西亚投资建设LED CSP项目，表明蔚蓝锂芯积极拓展国际市场，希望 增强全球竞争力，这会对LED行业产生积极影响。 每经记者｜朱成祥 每经编辑｜文多 丨 2025年8月19日 星期二丨 NO.1 久吾高科：拟发行可 ...

转自：证券时报 人民财讯8月8日电，三鑫医疗(300453)8月8日晚间公告，拟发行可转债募资不超5.3亿元，用于三鑫医疗 年产1000万束血液透析膜及1000万支血液透析器改扩建项目、三鑫医疗高性能血液净化设备及配套耗材 研发生产基地项目-新建年产3000万套血液透析管路生产线及配套工程建设项目、江西呈图康电子加速 器辐照灭菌生产线改扩建项目、补充流动资金。 ...

每经AI快讯，8月1日，精研科技（300709）(300709.SZ)公告称，拟发行可转债募资不超过5.8亿元，用 于新型消费电子与数据服务器精密MIM零部件及组件生产项目、总部及研发中心建设项目、精密模具 中心建设项目。 ...

人民财讯8月1日电，精研科技（300709）8月1日晚间公告，公司拟发行可转债募集资金不超过5.78亿元 (含本数)，扣除发行费用后，募集资金净额拟投资于新型消费电子与数据服务器精密MIM零部件及组件 生产项目、总部及研发中心建设项目、精密模具中心建设项目。 ...

智通财经APP讯，精研科技(300709.SZ)披露向不特定对象发行可转换公司债券预案，本次拟发行可转换 公司债券募集资金总额不超过5.78亿元(含本数)，初始转股价格不低于募集说明书公告日前二十个交易 日公司股票交易均价和前一个交易日公司股票交易均价。 本次发行扣除发行费用后，募集资金净额拟投资于新型消费电子与数据服务器精密MIM零部件及组件 生产项目、总部及研发中心建设项目、精密模具中心建设项目。 ...

Core Viewpoint - Jiangsu Leili plans to issue convertible bonds to raise up to 1.286 billion yuan for various production and development projects, enhancing its core competitiveness in the micro-motor and intelligent component manufacturing industry [1][2][4]. Fundraising and Investment Projects - The company aims to use the raised funds for projects including the production of laser radar motors, laser equipment galvanometer systems, automotive micro-motors, and components, as well as the establishment of a robotics control component R&D center and overseas production bases [2][3]. - The total investment for the "intelligent sensing laser radar and vehicle thermal management micro-motor, laser equipment galvanometer system production project" is planned at 229 million yuan, with 219 million yuan from the raised funds [2]. - The "automotive micro-motor and component production base and laboratory construction project" has a total investment of 287 million yuan, with 277 million yuan expected from the fundraising [2]. Overseas Expansion and Market Coverage - Jiangsu Leili plans to enhance its overseas presence to meet the growing international market demand, with investments in production bases in Malaysia, Vietnam, and Mexico totaling 440 million yuan, of which 410 million yuan will come from the raised funds [3]. - The company’s revenue distribution shows 53.35% from domestic markets and 46.65% from international markets for the 2024 fiscal year [3]. Financial Performance and Growth Strategy - In Q1 2025, Jiangsu Leili reported a revenue of 908 million yuan, a year-on-year increase of 25.81%, and a net profit attributable to shareholders of 94 million yuan, up 28.15% [1][7]. - The company aims for a sales target of 4.1 billion yuan for 2025, representing a 16.5% year-on-year growth [7]. R&D and Innovation - Jiangsu Leili has consistently increased its R&D investment, with amounts of 133 million yuan, 147 million yuan, and 168 million yuan from 2022 to 2024, maintaining a stable R&D expenditure ratio of around 4.77% of revenue [6]. - The company has expanded its product applications from home appliances to sectors such as new energy, medical devices, and industrial control through strategic acquisitions [5][6]. Dividend Policy - Since its listing, Jiangsu Leili has distributed a total of 960 million yuan in cash dividends, representing 47% of its cumulative net profit during this period [5][7].

Core Viewpoint - Lepu Medical reported a significant decline in financial performance for the year 2024, with a notable drop in revenue and net profit compared to the previous year [1][2]. Financial Performance Summary - The company's operating revenue for 2024 was 6.10 billion yuan, a decrease of 23.52% from 2023's 7.98 billion yuan [2]. - Net profit attributable to shareholders was 246.94 million yuan, down 80.37% from 1.26 billion yuan in 2023 [2]. - The net profit after deducting non-recurring gains and losses was 221.43 million yuan, reflecting an 80.28% decline from 1.12 billion yuan in the previous year [2]. - The net cash flow from operating activities was 734.64 million yuan, a decrease of 25.82% compared to 990.36 million yuan in 2023 [2]. Historical Comparison - In 2023, Lepu Medical's operating revenue was 7.98 billion yuan, down 24.78% from 2022 [3]. - The net profit attributable to shareholders in 2023 was 1.26 billion yuan, a decrease of 42.91% from 2022 [3]. - The net cash flow from operating activities in 2023 was 990.36 million yuan, down 64.51% from 2022 [3]. Profit Distribution Plan - The company approved a profit distribution plan, proposing a cash dividend of 1.35 yuan per 10 shares (including tax) to all shareholders, with no bonus shares [2].

制图：佘诗婕 星标 ★ IPO日报 精彩文章第一时间推送 据IPO日报汇总，3月24日至3月30日，即上周一周内，多家上市公司发布发行可转债募资公告。其中，3月28日，三友化工（600409.SH）拟公开发 行公司债券，规模不超过9亿元，美力科技（300611.SZ）拟发行可转债募资不超过3亿元。 另外，3月28日，上交所和深交所修订并发布了《上海证券交易所公司债券发行上市审核规则适用指引第3号——审核重点关注事项（2025年修订）》、 《深圳证券交易所公司债券发行上市审核业务指引第2号——审核重点关注事项（2025年修订）》，旨在进一步强化公司债券（含企业债券）发行准入监 管，提升审核透明度，推动市场高质量发展。 3月24日至3月30日发债情况汇总 制图：李昕 三家5年内多次募资 上周，多家上市公司发布公告，拟通过发行可转换债券募资，涵盖新能源汽车、跨境电商、机器人等领域，IPO日报整理发现，无锡振华 （605319.SH）、瑞鹄模具（002997.SZ）和双乐股份（301036.SZ）均为上市5年内多次募资。目前无锡振华发行可转债申请获上交所通过。 3月26日，无锡振华公告称，公司向不特定对象发行可转换公 ...